Jennifer S Gewandter1, Amber S Kleckner2, James H Marshall3, Jeffrey S Brown3, Lesley H Curtis4, Javier Bautista2, Robert H Dworkin5, Ian R Kleckner2, Noah Kolb6, Supriya G Mohile7, Karen M Mustian2. 1. Department of Anesthesiology and Perioperative Medicine, University of Rochester Medical Center, Rochester, NY, USA. jennifer_gewandter@urmc.rochester.edu. 2. Cancer Control, Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA. 3. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA. 4. Department of Population Health Sciences and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. 5. Department of Anesthesiology and Perioperative Medicine, University of Rochester Medical Center, Rochester, NY, USA. 6. The University of Vermont Medical Center, Burlington, VT, USA. 7. Department of Medicine, Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
Abstract
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling complication of many chemotherapies. We investigated the feasibility of using health plan claims and administrative data to identify CIPN occurrence by comparing patients who received neurotoxic and non-neurotoxic chemotherapies. METHODS: The sample included over 53,000,000 patients from two regional and one national insurer in the USA (> 400,000 exposed to chemotherapy). Peripheral neuropathy was identified using a broad definition (definition 1) and a specific definition (i.e., drug-induced polyneuropathy code) (definition 2). RESULTS: CIPN incidence as measured by definition 1 within 6 months of chemotherapy initiation was 18.1% and 6.2% for patients who received neurotoxic and non-neurotoxic chemotherapy, respectively (relative risk neurotoxic vs. non-neurotoxic (RR), 2.93 (95% CI, 2.87-2.98)). For definition 2, these incidences were 3.6% and 0.1% (RR, 25.2 (95% CI, 22.8-27.8)). The incidences of new analgesic prescriptions for neurotoxic and non-neurotoxic groups were as follows: gabapentin, 7.1%/1.7%; pregabalin, 0.69%/0.31%; and duloxetine, 0.78%/0.76%. The incidence of CIPN as defined by definitions 1 and 2 was low compared with that of published research studies, but the relative risk of CIPN among patients who received neurotoxic chemotherapies compared with those who received non-neurotoxic chemotherapies was high using definition 2. CONCLUSIONS: These data suggest that as used currently by clinicians, administrative codes likely underestimate CIPN incidence. Thus, studies using administrative data to estimate CIPN incidence are not currently feasible. However, the drug-induced polyneuropathy code is a specific indicator of CIPN in administrative data and may be useful for investigating predictors or potentially preventive therapies of CIPN.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling complication of many chemotherapies. We investigated the feasibility of using health plan claims and administrative data to identify CIPN occurrence by comparing patients who received neurotoxic and non-neurotoxic chemotherapies. METHODS: The sample included over 53,000,000 patients from two regional and one national insurer in the USA (> 400,000 exposed to chemotherapy). Peripheral neuropathy was identified using a broad definition (definition 1) and a specific definition (i.e., drug-induced polyneuropathy code) (definition 2). RESULTS: CIPN incidence as measured by definition 1 within 6 months of chemotherapy initiation was 18.1% and 6.2% for patients who received neurotoxic and non-neurotoxic chemotherapy, respectively (relative risk neurotoxic vs. non-neurotoxic (RR), 2.93 (95% CI, 2.87-2.98)). For definition 2, these incidences were 3.6% and 0.1% (RR, 25.2 (95% CI, 22.8-27.8)). The incidences of new analgesic prescriptions for neurotoxic and non-neurotoxic groups were as follows: gabapentin, 7.1%/1.7%; pregabalin, 0.69%/0.31%; and duloxetine, 0.78%/0.76%. The incidence of CIPN as defined by definitions 1 and 2 was low compared with that of published research studies, but the relative risk of CIPN among patients who received neurotoxic chemotherapies compared with those who received non-neurotoxic chemotherapies was high using definition 2. CONCLUSIONS: These data suggest that as used currently by clinicians, administrative codes likely underestimate CIPN incidence. Thus, studies using administrative data to estimate CIPN incidence are not currently feasible. However, the drug-induced polyneuropathy code is a specific indicator of CIPN in administrative data and may be useful for investigating predictors or potentially preventive therapies of CIPN.
Authors: S Tesfaye; L K Stevens; J M Stephenson; J H Fuller; M Plater; C Ionescu-Tirgoviste; A Nuber; G Pozza; J D Ward Journal: Diabetologia Date: 1996-11 Impact factor: 10.122
Authors: Marta Seretny; Gillian L Currie; Emily S Sena; Sabrina Ramnarine; Robin Grant; Malcolm R MacLeod; Leslie A Colvin; Marie Fallon Journal: Pain Date: 2014-09-23 Impact factor: 6.961
Authors: Arya Shah; E Matthew Hoffman; Michelle L Mauermann; Charles L Loprinzi; Anthony J Windebank; Christopher J Klein; Nathan P Staff Journal: J Neurol Neurosurg Psychiatry Date: 2018-02-08 Impact factor: 10.154
Authors: Michael J Raphael; Hadas D Fischer; Kinwah Fung; Peter C Austin; Geoffrey M Anderson; Christopher M Booth; Simron Singh Journal: Clin Colorectal Cancer Date: 2017-03-24 Impact factor: 4.481
Authors: Dawn L Hershman; Christina Lacchetti; Robert H Dworkin; Ellen M Lavoie Smith; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Patrick Gavin; Antoinette Lavino; Maryam B Lustberg; Judith Paice; Bryan Schneider; Mary Lou Smith; Tom Smith; Shelby Terstriep; Nina Wagner-Johnston; Kate Bak; Charles L Loprinzi Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Susan G Dorsey; Ian R Kleckner; Debra Barton; Karen Mustian; Ann O'Mara; Diane St Germain; Guido Cavaletti; Suzanne C Danhauer; Dawn L Hershman; Andrea G Hohmann; Ahmet Hoke; Judith O Hopkins; Katherine P Kelly; Charles L Loprinzi; Howard L McLeod; Supriya Mohile; Judith Paice; Julia H Rowland; Daniela Salvemini; Rosalind A Segal; Ellen Lavoie Smith; Worta McCaskill Stevens; Michelle C Janelsins Journal: J Natl Cancer Inst Date: 2019-06-01 Impact factor: 13.506
Authors: Myra Barginear; Amylou C Dueck; Jacob B Allred; Craig Bunnell; Harvey J Cohen; Rachel A Freedman; Arti Hurria; Gretchen Kimmick; Jennifer G Le-Rademacher; Stuart Lichtman; Hyman B Muss; Lawrence N Shulman; M Sitiki Copur; David Biggs; Bhuvaneswari Ramaswamy; Jacqueline M Lafky; Aminah Jatoi Journal: Oncologist Date: 2018-11-08
Authors: Sruthi Adimadhyam; Erin F Barreto; Noelle M Cocoros; Sengwee Toh; Jeffrey S Brown; Judith C Maro; Jacqueline Corrigan-Curay; Gerald J Dal Pan; Robert Ball; David Martin; Michael Nguyen; Richard Platt; Xiaojuan Li Journal: J Am Soc Nephrol Date: 2020-10-19 Impact factor: 10.121
Authors: Arjun Gupta; Leonce Nshuti; Udhayvir S Grewal; Ramy Sedhom; Devon K Check; Helen M Parsons; Anne H Blaes; Beth A Virnig; Maryam B Lustberg; Ishwaria M Subbiah; Ryan D Nipp; Sydney M Dy; Stacie B Dusetzina Journal: JCO Oncol Pract Date: 2021-09-24
Authors: Marie Selvy; Bruno Pereira; Nicolas Kerckhove; Jérôme Busserolles; Fadila Farsi; Virginie Guastella; Patrick Merle; Denis Pezet; David Balayssac Journal: Support Care Cancer Date: 2021-01-05 Impact factor: 3.359
Authors: Nilesh M Agalave; Prapti H Mody; Thomas A Szabo-Pardi; Han S Jeong; Michael D Burton Journal: Front Immunol Date: 2021-04-12 Impact factor: 7.561